Trial Profile

A Phase 3, Randomized, Multicenter, Parallel-arm, Double-blind Study to Compare Efficacy and Safety of EG1206A (EirGenix' Pertuzumab) and Perjeta® (Pertuzumab) Sourced From EU as Neoadjuvant Treatment in Combination With Trastuzumab and Chemotherapy in Patients With HER2-positive Hormone Receptor-negative Early Breast Cancer

Status: Not yet recruiting

Phase of Trial: Phase III

Latest Information Update: 09 Apr 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Pertuzumab (Primary) ; Carboplatin; Docetaxel; Pertuzumab; Trastuzumab
Indications Carcinoma; Early breast cancer; HER2 positive breast cancer; Male breast cancer
Focus Registrational; Therapeutic Use
Acronyms EGC102
Sponsors EirGenix

19 Mar 2025 Status changed from planning to not yet recruiting.
08 May 2023 According to an EirGenix, Inc. media release, it is expected that the evaluation of the primary end point indicators will be completed within two (2) years.
08 May 2023 New trial record

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com